| ACE | Angiotensin converting enzyme |
| aPL | Antiphospholipid antibodies |
| APS | Antiphospholipid syndrome |
| β2GPI | Beta-2 glycoprotein I |
| BMI | Body mass index |
| CAT | Cancer associated thrombosis |
| CI | Confidence interval |
| COVID19 | SARS-CoV2 disease |
| CVT | Cerebral vein thrombosis |
| DAMPs | Damage-Associated Molecular Patterns |
| DNA | Desoxyribonucleic acid |
| DVT | Deep vein thrombosis |
| ERS | European Respiratory Society |
| ESC | European society of cardiology |
| FVL | Leiden factor V |
| HR | Hazard ratio |
| ICU | Intensive care unit |
| IL | Interleukin |
| LAC | Lupus anticoagulant |
| MP | Microparticles |
| NETs | Neutrophil extracellular traps |
| NO | Nitric oxide |
| NOS | nitrogen species |
| OR | Odds ratio |
| PAI | Plasminogen Activator Inhibitor-1 |
| PAMPs | Pathogen Associated Molecular Patterns |
| PE | Pulmonary embolism |
| PGM | Prothrombin G20210A Gene Mutation |
| PLT | Platelets |
| PMNs | Polymorphonuclear neutrophils |
| ROS | Reactive oxygen species |
| RVT | Residual venous thrombosis |
| TF | Tissue factor |
| TLR | Toll like receptor |
| VTE | Venous thromboembolism |
| vWF | Von Willebrand factor |
| WBC | White blood cells |